Ginkgo Bioworks Holdings (NYSE:DNA), which develops platforms for cell programming, has multiple, positive potential catalysts and a rather low valuation. Moreover, the shares should benefit from investors’ recent interest in buying small-cap stocks that have lost a great deal of their value. Given that analysts also expect Ginkgo’s top line to rebound sharply in 2025, I believe that risk-tolerant growth investors who are looking for a biotech play can consider buying a small amount of DNA stock at this poi ...